FDA seeks permanent injunctions against two stem cell clinics
FDA is seeking permanent injunctions to stop two stem cell clinics from marketing stem cell products without FDA approval
FDA is seeking permanent injunctions to stop two stem cell clinics from marketing stem cell products without FDA approval
FDA permits marketing of new endoscopic device for treating gastrointestinal bleeding
Statement from FDA Commissioner Scott Gottlieb, M.D., on the public health benefits from enactment of menu labeling
FDA approves Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer
FDA, FTC take action against companies misleading kids with e-liquids that resemble children’s juice boxes, candies and cookies
FDA Commissioner Scott Gottlieb, M.D. remarks to a U.S. Senate Subcommittee on Appropriations on the FDA’s Fiscal Year 2019 budget
FDA announces several new enforcement actions and a Youth Tobacco Prevention Plan to stop youth use of, and access to, JUUL and other e-cigarettes.
FDA authorized the first test to identify the emerging pathogen Candida auris, which can cause serious infections in hospitalized patients.
FDA announces new steps to encourage more widespread innovation and development of new treatments for opioid use disorder
FDA announces new steps to encourage and support the development of treatment options for people with opioid use disorder
Cantrell Drug Company prohibited from manufacturing and distributing sterile drug products in violation of the law
FDA Commissioner Scott Gottlieb, M.D. remarks to the U.S. House Committee on Appropriations on the FDA’s Fiscal Year 2019 budget
FDA approved Crysvita (burosumab), the first drug approved to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH), a rare form of rickets.
One way FDA oversees food safety is through monitoring of contaminants in food, such as arsenic, assessing potential exposure and taking steps to reduce exposure
The FDA is releasing the Medical Device Safety Action Plan that outlines our vision for how FDA can continue to enhance our programs and processes to assure the safety of medical devices
: El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) tomó una medida importante para proteger mejor a los consumidores de los peligros de los productos de cafeína altamente concentrada y pura.
Today, the U.S. Food and Drug Administration took an important step to better protect consumers from the dangers of highly concentrated and pure caffeine products.
The FDA today finalized two guidances to drive the efficient development of a novel technology that scans a person’s DNA to diagnose genetic diseases, which are usually hereditary, and guide medical treatments.
FDA permits marketing of first medical device to use artificial intelligence to detect greater than a mild level of diabetic retinopathy in the eye of adults who have diabetes.